Cargando…

Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia

Detalles Bibliográficos
Autores principales:	Tam, Constantine, Munoz, Javier, Cull, Gavin, Opat, Stephen, Allewelt, Heather, Zhang, Xiaoping, Stern, Jennifer C., Hilger, James, By, Kunthel, Cohen, Aileen, Tedeschi, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043571/ https://www.ncbi.nlm.nih.gov/pubmed/36999005 http://dx.doi.org/10.1097/HS9.0000000000000870

Ejemplares similares

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia
por: Tam, Constantine S., et al.
Publicado: (2023)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

Correction: Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study
por: Cull, Gavin, et al.
Publicado: (2021)

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
por: Tam, Constantine S., et al.
Publicado: (2022)

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
por: Tam, Constantine S., et al.
Publicado: (2020)

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES
por: Tam, Constantine, et al.
Publicado: (2023)

Efficacy of Zanubrutinib in the Treatment of Bing–Neel Syndrome
por: Wong, Jonathan, et al.
Publicado: (2018)

Rare Richter Transformation of Chronic Lymphocytic Lymphoma to Hodgkin Lymphoma
por: Buckley, Tinera, et al.
Publicado: (2021)

P1679: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR): RESULTS FROM THE PHASE 3 ASPEN TRIAL LONG-TERM FOLLOW-UP
por: Tedeschi, Alessandra, et al.
Publicado: (2023)

P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB
por: Shadman, Mazyar, et al.
Publicado: (2023)

An Approach to Diagnosis of Richter Transformation in Chronic Lymphocytic Leukemia
por: Broadway-Duren, Jackie
Publicado: (2022)

P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
por: Munir, Talha, et al.
Publicado: (2023)

Detection of early seeding of Richter transformation in chronic lymphocytic leukemia
por: Nadeu, Ferran, et al.
Publicado: (2022)

Treatment of Richter Transformation of Chronic Lymphocytic Leukemia in the Modern Era
por: Briski, Robert, et al.
Publicado: (2023)

P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
por: Dimopoulos, M., et al.
Publicado: (2022)

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
por: Molica, Stefano, et al.
Publicado: (2023)

Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
por: Fabbri, Giulia, et al.
Publicado: (2013)

Secondary Hemophagocytic Syndrome Associated with Richter's Transformation in Chronic Lymphocytic Leukemia
por: El-Haj, Nura, et al.
Publicado: (2014)

Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents
por: Tadmor, Tamar, et al.
Publicado: (2021)

Biology and Treatment of Richter Transformation
por: Condoluci, Adalgisa, et al.
Publicado: (2022)

Cytogenomic features of Richter transformation
por: Woroniecka, Renata, et al.
Publicado: (2023)

A Carotid Body Tumour Mimicking Richter’s Transformation of Chronic Lymphocytic Leukaemia
por: Qamar, Younus, et al.
Publicado: (2022)

Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
por: Zhou, Keshu, et al.
Publicado: (2021)

P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE
por: Brown, Jennifer R., et al.
Publicado: (2023)

Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome
por: Wang, Yucai, et al.
Publicado: (2021)

P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)
por: Eichhorst, Barbara, et al.
Publicado: (2023)

Sviatoslav Richter
Publicado: (1998)

Sviatoslav Richter.
por: Beethoven, Ludwig van, 1770-1827
Publicado: (1998)

Richter Syndrome
por: Condoluci, Adalgisa, et al.
Publicado: (2021)

Zanubrutinib in lymphoproliferative disorders: a comprehensive review
por: Muñoz, Javier, et al.
Publicado: (2022)

Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation
por: Ortiz-Maldonado, Valentín, et al.
Publicado: (2022)

The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation
por: Visentin, Andrea, et al.
Publicado: (2021)

Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation
por: Hing, Zachary A., et al.
Publicado: (2023)

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
por: Hillmen, Peter, et al.
Publicado: (2023)

Richter Transformation: Clinical Manifestations, Evaluation, and Management
por: Douglas, Melanie
Publicado: (2022)

Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First
por: Deshpande, Anagha, et al.
Publicado: (2022)

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
por: Tatarczuch, Maciej, et al.
Publicado: (2023)

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
por: Opat, Stephen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t4p2mds5qkj1bbfn10ve31eq4n